Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.6 EUR
33.87 M EUR
161.96 M EUR
18.53 M
About SHIN NIPPON BIOMEDICAL LABORATORIES
Sector
CEO
Ryoichi Nagata
Website
Headquarters
Tokyo
Founded
1957
ISIN
JP3379950003
FIGI
BBG000BSTF82
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells. The Clinical Business segment provides the support services for clinical trials and related statistical, analytical, and consulting services for all aspects of new drug development. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of YB3 is 10.2 EUR — it has increased by 4.08% in the past 24 hours. Watch SHIN NIPPON BIOMED.LAB. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SHIN NIPPON BIOMED.LAB. stocks are traded under the ticker YB3.
YB3 stock has risen by 7.94% compared to the previous week, the month change is a 12.71% rise, over the last year SHIN NIPPON BIOMED.LAB. has showed a −1.92% decrease.
We've gathered analysts' opinions on SHIN NIPPON BIOMED.LAB. future price: according to them, YB3 price has a max estimate of 22.21 EUR and a min estimate of 9.01 EUR. Watch YB3 chart and read a more detailed SHIN NIPPON BIOMED.LAB. stock forecast: see what analysts think of SHIN NIPPON BIOMED.LAB. and suggest that you do with its stocks.
YB3 stock is 3.92% volatile and has beta coefficient of 1.12. Track SHIN NIPPON BIOMED.LAB. stock price on the chart and check out the list of the most volatile stocks — is SHIN NIPPON BIOMED.LAB. there?
Today SHIN NIPPON BIOMED.LAB. has the market capitalization of 438.95 M, it has increased by 1.64% over the last week.
Yes, you can track SHIN NIPPON BIOMED.LAB. financials in yearly and quarterly reports right on TradingView.
SHIN NIPPON BIOMED.LAB. is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
YB3 earnings for the last quarter are 0.18 EUR per share, whereas the estimation was 0.17 EUR resulting in a 7.99% surprise. The estimated earnings for the next quarter are 0.13 EUR per share. See more details about SHIN NIPPON BIOMED.LAB. earnings.
SHIN NIPPON BIOMED.LAB. revenue for the last quarter amounts to 43.48 M EUR, despite the estimated figure of 33.82 M EUR. In the next quarter, revenue is expected to reach 50.93 M EUR.
YB3 net income for the last quarter is 7.55 M EUR, while the quarter before that showed 708.65 K EUR of net income which accounts for 965.87% change. Track more SHIN NIPPON BIOMED.LAB. financial stats to get the full picture.
SHIN NIPPON BIOMED.LAB. dividend yield was 3.29% in 2023, and payout ratio reached 37.63%. The year before the numbers were 1.82% and 34.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 26, 2024, the company has 1.34 K employees. See our rating of the largest employees — is SHIN NIPPON BIOMED.LAB. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHIN NIPPON BIOMED.LAB. EBITDA is 25.18 M EUR, and current EBITDA margin is 22.80%. See more stats in SHIN NIPPON BIOMED.LAB. financial statements.
Like other stocks, YB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHIN NIPPON BIOMED.LAB. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHIN NIPPON BIOMED.LAB. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHIN NIPPON BIOMED.LAB. stock shows the buy signal. See more of SHIN NIPPON BIOMED.LAB. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.